0
Abstract: Poster Presentations |

THE DIAGNOSIS OF MEDIASTINAL LYMPHADENOPATHY BY ENDOBRONCHIAL ULTRASOUND GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION IN AN ACADEMIC CANCER INSTITUTION FREE TO VIEW

Marcus P. Kennedy, MD, MRCP*; Carlos A. Jimenez, MD; Rodolfo C. Morice, MD; Ashwini D. Mhatre, MD; Saritha Ravella, MD; Mona Sarkiss, MD, PhD; Tina Fanning, MD; Xiudong Lei, PhD; George A. Eapen, MD
Author and Funding Information

MD Anderson Cancer Center, Houston, TX


Chest


Chest. 2007;132(4_MeetingAbstracts):591b. doi:10.1378/chest.132.4_MeetingAbstracts.591b
Text Size: A A A
Published online

Abstract

PURPOSE: The utility of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) in lung cancer staging has been defined. We investigated the yield of EBUS-TBNA in a heterogeneous population of patients with mediastinal lymphadenopathy secondary to suspected cancer (lung and nonlung) or recurrence after therapy in a large academic cancer institute.

METHODS: A retrospective review was performed of all patients referred to our institution between August 2005 and September 2006 for real-time EBUS-TBNA for the investigation of mediastinal lymphadenopathy. EBUS-TBNA was performed in all cases using a linear array ultrasonic bronchscope (Olympus XBF-UC 160F) under intravenous anesthesia with on-site cytopathologic support for assessment of specimen adequacy. The EBUS-TBNA result was categorized as malignant, benign disease, normal/benign hyperplasia or inadequate. These results were compared to a reference standard of definitive pathological tissue diagnosis or a composite of ≥6 month's clinical follow-up with radiographic imaging.

RESULTS: 153 patients underwent 154 EBUS-TBNA procedures for mediastinal adenopathy. Adequate lymphoid tissue was obtained in 147/154 (95.5%) procedures. The 144 patients in whom a reference standard was available (n=107 definitive pathological tissue diagnosis) are included in the following analysis. EBUS -TBNA was positive in 59/70 (84.3%) patients ultimately diagnosed with malignant mediastinal lymphadenopathy. EBUS TBNA was definitive in 18/24 (75%) patients with benign disease. Of the remaining 50 patients that were found to have normal lymphoid tissue or benign hyperplasia, EBUS-TBNA obtained adequate sample in 46 (92%).

CONCLUSION: In a heterogeneous population of lung and nonlung cancer patients in an academic cancer institute, EBUS-TBNA is a minimally invasive accurate diagnostic technique with a high yield in patients with mediastinal lymphadenopathy and may obviate the need for invasive procedures such as mediastinoscopy.

CLINICAL IMPLICATIONS: Predictors for positive EBUS-TBNA yield including cancer history and treatment, lymph node pathology, size, site and PET-SUV are currently being analyzed.

DISCLOSURE: Marcus Kennedy, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543